Arvinas, Inc. ARVN
Arvinas, Inc. (Nasdaq: ARVN) is an oncology drug developer. Its lead program, ARV-393, is in Phase 1 for Relapsed/refractory lymphoma (BCL6 PROTAC). Its next catalyst on record is ARV-393: Monotherapy data (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ARV-393 — Monotherapy data (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ARV-393 | B-cell lymphoma | small molecule | Phase 1 |
| ARV-806 | KRAS G12D solid tumors | small molecule | Phase 1 |
| ARV-102 | PSP/Parkinson's (LRRK2) | small molecule | Phase 1 |
| ARV-027 | SBMA | small molecule | Phase 1 |
| ARV-6723 | Undisclosed | small molecule | Pre-clinical |
Recent results and decisions
- May 1, 2026approval FDA approved VEPPANU, first PROTAC, ahead of June 5, 2026 PDUFA; VERITAC-2 ESR1m: median PFS 5.0 vs 2.1 months, HR 0.57, p=0.0001.
This approval marks the first time the FDA has approved a PROteolysis TArgeting Chimera (PROTAC), a type of heterobifunctional protein degrader therapy.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.